# GLP-1s for $50 a Month? 14 Million Medicare Recipients May Be Eligible
Medicare has opened access to GLP-1 receptor agonist medications at a $35 monthly cap for seniors with diabetes and cardiovascular disease. An estimated 14 million Medicare beneficiaries qualify for this pricing on drugs like semaglutide and tirzepatide.
The policy applies to Part D prescription drug plans and represents a substantial reduction from typical out-of-pocket costs. Before this change, many seniors paid hundreds of dollars monthly for these medications. The $35 cap, negotiated as part of the Inflation Reduction Act, targets individuals managing type 2 diabetes, heart disease, or obesity-related conditions.
GLP-1 drugs have reshaped diabetes and weight management treatment. These medications work by mimicking glucagon-like peptide-1, a hormone that regulates blood sugar and appetite. Clinical trials show they reduce cardiovascular events in people with heart disease and lower blood sugar more effectively than older diabetes medications.
Access remains conditional on meeting specific eligibility requirements. Beneficiaries must enroll in a Medicare Part D plan that covers their chosen GLP-1 medication. Not all formulations qualify for the same pricing tier. Some plans may require prior authorization or step therapy, meaning patients try other treatments first.
Experts note the policy addresses a real barrier to treatment. High costs previously prevented many eligible seniors from accessing these medications despite clinical benefits. Dr. [specific researchers' names would be included if provided in source material] have documented how affordability directly impacts medication adherence in older populations.
Enrollment periods limit when seniors can switch plans to access lower costs. Those with current Part D coverage can switch during the Annual Enrollment Period from October through December. New Medicare beneficiaries should compare plans during their initial enrollment window.
Patients should verify their specific